NCT02098161View on ClinicalTrials.gov

LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 18, 2014

Primary Completion Date

May 19, 2022

Study Completion Date

May 19, 2022

Conditions
Polycythemia Vera, Post-Polycythemic Myelofibrosis PhasePrimary MyelofibrosisSecondary Myelofibrosis
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Smac Mimetic LCL161

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER